JP2014501766A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014501766A5 JP2014501766A5 JP2013547804A JP2013547804A JP2014501766A5 JP 2014501766 A5 JP2014501766 A5 JP 2014501766A5 JP 2013547804 A JP2013547804 A JP 2013547804A JP 2013547804 A JP2013547804 A JP 2013547804A JP 2014501766 A5 JP2014501766 A5 JP 2014501766A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- cycloalkyl
- group
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 239000001257 hydrogen Substances 0.000 claims 18
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 claims 18
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 14
- 239000000651 prodrug Substances 0.000 claims 14
- 229940002612 prodrugs Drugs 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- 239000011780 sodium chloride Substances 0.000 claims 14
- 239000012453 solvate Substances 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 201000010099 disease Diseases 0.000 claims 12
- 125000000623 heterocyclic group Chemical group 0.000 claims 12
- 125000005842 heteroatoms Chemical group 0.000 claims 10
- 229910052760 oxygen Inorganic materials 0.000 claims 10
- 229910052717 sulfur Inorganic materials 0.000 claims 10
- 125000000547 substituted alkyl group Chemical group 0.000 claims 9
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- -1 nitro, hydroxy Chemical group 0.000 claims 8
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000004432 carbon atoms Chemical group C* 0.000 claims 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 4
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 4
- 101710043635 PTK2B Proteins 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 230000002062 proliferating Effects 0.000 claims 4
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 3
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 3
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 3
- 125000003107 substituted aryl group Chemical group 0.000 claims 3
- 206010003816 Autoimmune disease Diseases 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 125000001091 aminosulfinyl group Chemical group [H]N([H])S(*)=O 0.000 claims 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 2
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 201000009910 diseases by infectious agent Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 200000000018 inflammatory disease Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001404 mediated Effects 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000240 adjuvant Effects 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 230000001028 anti-proliferant Effects 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000861 pro-apoptotic Effects 0.000 claims 1
- 0 Cc1c(*)c(*)c(*)c(Nc2c(C(*)(*)CN3)c3nc(Nc3c(*)c(C)c(*)c(*)c3*)n2)c1* Chemical compound Cc1c(*)c(*)c(*)c(Nc2c(C(*)(*)CN3)c3nc(Nc3c(*)c(C)c(*)c(*)c3*)n2)c1* 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110002776.3 | 2011-01-07 | ||
| CN201110002776.3A CN102093364B (zh) | 2011-01-07 | 2011-01-07 | 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物 |
| US201161457217P | 2011-02-02 | 2011-02-02 | |
| US61/457,217 | 2011-02-02 | ||
| PCT/CN2012/070122 WO2012092880A1 (fr) | 2011-01-07 | 2012-01-07 | Dérivés de 2,4-diamino-6,7-dihydro-5h-pyrrolo[2,3]pyrimidine comme inhibiteurs de fak/pyk2 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014501766A JP2014501766A (ja) | 2014-01-23 |
| JP2014501766A5 true JP2014501766A5 (fr) | 2015-02-19 |
| JP5961628B2 JP5961628B2 (ja) | 2016-08-02 |
Family
ID=44126650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013547804A Expired - Fee Related JP5961628B2 (ja) | 2011-01-07 | 2012-01-07 | ＦＡＫ／Ｐｙｋ２阻害剤である２，４−ジアミノ−６，７−ジヒドロ−５Ｈ−ピロロ［２，３］ピリミジン誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9428508B2 (fr) |
| EP (1) | EP2661437B1 (fr) |
| JP (1) | JP5961628B2 (fr) |
| KR (2) | KR101811938B1 (fr) |
| CN (1) | CN102093364B (fr) |
| AU (1) | AU2012204982B2 (fr) |
| CA (1) | CA2823969C (fr) |
| WO (1) | WO2012092880A1 (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103476776B (zh) * | 2011-01-07 | 2016-09-28 | 北京赛林泰医药技术有限公司 | 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物 |
| CN102093364B (zh) * | 2011-01-07 | 2015-01-28 | 北京赛林泰医药技术有限公司 | 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物 |
| CN104892585B (zh) * | 2014-03-06 | 2018-07-03 | 山东轩竹医药科技有限公司 | 嘧啶衍生物类间变性淋巴瘤激酶抑制剂 |
| CN107108586B (zh) * | 2014-09-29 | 2020-07-10 | 山东轩竹医药科技有限公司 | 多环类间变性淋巴瘤激酶抑制剂 |
| WO2018007331A1 (fr) * | 2016-07-08 | 2018-01-11 | F. Hoffmann-La Roche Ag | Dérivés fusionnés de pyrimidine |
| JP6980751B2 (ja) | 2016-07-14 | 2021-12-15 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 縮合ピリミジン誘導体 |
| CN113912586B (zh) | 2016-08-31 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | 氧代吡啶酰胺类衍生物、其制备方法及其在医药上的应用 |
| CN107936024B (zh) * | 2016-10-12 | 2021-04-30 | 北京赛林泰医药技术有限公司 | 一种间变性淋巴瘤激酶抑制剂及其制备方法和用途 |
| CN108276410B (zh) * | 2017-01-06 | 2021-12-10 | 首药控股(北京)股份有限公司 | 一种间变性淋巴瘤激酶抑制剂及其制备方法和用途 |
| CN108456210A (zh) * | 2017-02-22 | 2018-08-28 | 北京赛林泰医药技术有限公司 | 一种alk酪氨酸激酶抑制剂的多晶型物及其制备方法 |
| SI3612531T1 (sl) | 2017-04-18 | 2022-11-30 | Shanghai Fochon Pharmaceutical Co., Ltd. | Sredstva, ki sprožajo apoptozo |
| KR101992621B1 (ko) | 2017-12-07 | 2019-09-27 | 주식회사 온코빅스 | 암세포 성장 억제 효과를 나타내는 신규한 피리미딘 유도체 및 그를 포함하는 약제학적 조성물 |
| CN110526915B (zh) * | 2018-05-25 | 2022-02-01 | 首药控股(北京)股份有限公司 | 一种间变性淋巴瘤激酶抑制剂的制备方法 |
| KR102377007B1 (ko) * | 2018-09-20 | 2022-03-22 | 한미약품 주식회사 | 상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 융합 피리미딘 골격 설폰아마이드 유도체 |
| EP3842435A4 (fr) * | 2018-09-20 | 2022-05-11 | Hanmi Pharm. Co., Ltd. | Nouveau dérivé de sulfonamide présentant un squelette de pyrimidine fusionné, ayant un effet inhibiteur de mutation du récepteur du facteur de croissance épidermique |
| CN113087709A (zh) * | 2020-01-09 | 2021-07-09 | 沈阳药科大学 | 吡咯并嘧啶类衍生物及其制备方法和应用 |
| CN115368364A (zh) * | 2021-05-19 | 2022-11-22 | 四川大学 | 7H-吡咯并[2,3-d]嘧啶衍生物及其制备方法和用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0782174A (ja) | 1993-09-17 | 1995-03-28 | Takeda Chem Ind Ltd | 抗腫瘍剤 |
| GB0115393D0 (en) * | 2001-06-23 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| US7384937B2 (en) * | 2002-11-06 | 2008-06-10 | Bristol-Myers Squibb Co. | Fused heterocyclic compounds and use thereof |
| EP1713806B1 (fr) * | 2004-02-14 | 2013-05-08 | Irm Llc | Composes et compositions tenant lieu d'inhibiteurs de la proteine kinase |
| DE102006016426A1 (de) | 2006-04-07 | 2007-10-11 | Merck Patent Gmbh | Neuartige Cyclobutyl-Verbindungen als Kinase-Inhibitoren |
| TWI398252B (zh) * | 2006-05-26 | 2013-06-11 | Novartis Ag | 吡咯并嘧啶化合物及其用途 |
| EP2271631B1 (fr) | 2008-04-22 | 2018-07-04 | Portola Pharmaceuticals, Inc. | Inhibiteurs de protéines kinases |
| CN102093364B (zh) * | 2011-01-07 | 2015-01-28 | 北京赛林泰医药技术有限公司 | 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物 |
-
2011
- 2011-01-07 CN CN201110002776.3A patent/CN102093364B/zh active Active
-
2012
- 2012-01-07 CA CA2823969A patent/CA2823969C/fr not_active Expired - Fee Related
- 2012-01-07 AU AU2012204982A patent/AU2012204982B2/en not_active Ceased
- 2012-01-07 EP EP12732345.9A patent/EP2661437B1/fr not_active Not-in-force
- 2012-01-07 KR KR1020157037254A patent/KR101811938B1/ko active IP Right Grant
- 2012-01-07 WO PCT/CN2012/070122 patent/WO2012092880A1/fr active Application Filing
- 2012-01-07 KR KR1020137020933A patent/KR20130122778A/ko active Search and Examination
- 2012-01-07 JP JP2013547804A patent/JP5961628B2/ja not_active Expired - Fee Related
- 2012-01-07 US US13/978,475 patent/US9428508B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014501766A5 (fr) | ||
| JP2016503799A5 (fr) | ||
| JP2016121196A5 (fr) | ||
| CY1120104T1 (el) | Αναστολεις της syk | |
| JP2015520140A5 (fr) | ||
| JP2014521688A5 (fr) | ||
| JP2018536634A5 (fr) | ||
| JP2018522879A5 (fr) | ||
| JP2017519754A5 (fr) | ||
| MX2017007748A (es) | Compuestos de heteroarilo anulares fusionados y su uso como inhibidores del receptor de la tirocina cinasa (trk). | |
| RU2016150486A (ru) | Ингибиторы бета-лактамазы | |
| RU2016134751A (ru) | Соединения | |
| JP2016518328A5 (fr) | ||
| JP2015535277A5 (fr) | ||
| JP2019524883A5 (fr) | ||
| JP2017508782A5 (fr) | ||
| JP2015531366A5 (fr) | ||
| JP2013510123A5 (fr) | ||
| JP2015508103A5 (fr) | ||
| JP2018527301A5 (ja) | アジリジン含有ｄｎａアルキル化剤 | |
| JP2019531279A5 (fr) | ||
| JP2015522650A5 (fr) | ||
| CY1120836T1 (el) | Ενωσεις 1,3,4-θειαδιαζοαης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου | |
| JP2015508092A5 (fr) | ||
| CY1123285T1 (el) | Ενωσεις 6-αρυλ-4-(μορφολιν-4-υλ)-1η-πυριδιν-2-ονης χρησιμες για τη θεραπεια καρκινου και διαβητη |